Kornimate/medical-research-clean huggingface dataset:
preliminary evaluation of an osteopathic manipulative treatment (omt) to prevent motion sickness symptoms

Conditions: Motion Sickness

Summary: motion sickness directly impacts the readiness of the army's aviation units. severe motion sickness results in the dismissal of pilot and air crew candidates during initial training, while minor to moderate symptoms can be distracting during flight. the current medications on the market that target motion sickness symptoms are prohibited for use before flight. osteopathic manipulative techniques are a low to no cost option, which lacks side effects, that allows doctor of osteopathic medicine flight surgeons the opportunity to treat crew members without the use of pharmaceuticals. if effective, these techniques could be used to ensure aircrew readiness. given the paucity of research on such a technique, a small, pilot study was conducted to demonstrate potential for such an approach.


Eligibility criteria:
inclusion criteria: * must have normal hearing, vision or corrected to normal vision, and cognitive function as determined by self-report and review on demographics and personal history questionnaire. * must have obtained at minimum 6 hours of sleep prior to data collection, as assessed by self-report. * must have refrained from consumption of alcohol and medications that impact motion sickness symptoms for a minimum of 16 hours prior to each test session, assessed by self-report. exclusion criteria: 1. must not be currently taking any medications that may affect the vestibular system as assessed by self-report and at the discretion of the study physician. 2. must not have a history of vestibular disorders as assessed by self-report.
thyroid disorders in malaysia: a nationwide multicentre study

Conditions: Hypothyroidism; Subclinical Hypothyroidism; Hyperthyroidism; Subclinical Hyperthyroidism; Graves Disease; Hashimoto's Thyroiditis; Iodine Deficiency; Genetic Susceptibility

Summary: this will be a population based study looking at the prevalence of thyroid disorders in malaysia (including hypo- and hyperthyroidism, subclinical hypo- or hyperthyroidism) and its association with different ethnicity and iodine status. the study will also look at genetic susceptibility for autoimmune thyroid disorders in the malaysian population general hypotheses: the prevalence of thyroid disorders in malaysia is 10% for hypothyroidism and 2% for hyperthyroidism hypo- and hyperthyroidism is associated with iodine status in our population there are different susceptibility gene for autoimmune thyroid disorder in different ethnicity in our population

this will be a cross-sectional population based study involving malaysian adults (aged 18 year old and above). cluster sampling will be used to select respondents that will be representative of the malaysian population. selected respondent will be interviewed, anthropometric measurement taken, blood and urine sample taken. blood will be analyzed for thyroid function (thyroxine, triiodothyronine and thyroid stimulating hormone), autoantibodies (anti-thyroperoxidase and anti-thyroglobulin). urine will be analyzed for urinary iodine. those diagnosed with autoimmune thyroid disorders with strong family history of thyroid disorders (multiplex multi-generation family involvement) will have their blood sent for whole exome sequencing and linkage analysis done to identify possible susceptible gene for autoimmune thyroid disorders respondents detected to have hypo- or hyper- and subclinical hypo- or hyperthyroidism will be referred to their nearest health centre for further evaluation and treatment appropriate for their condition.

Eligibility criteria:
inclusion criteria: * aged equal or more than 18 years old at the time of sampling * malaysian citizen exclusion criteria: * respondents who did not give consent

Keywords: hyperthyroidism hypothyroidism autoimmune thyroid disorders iodine deficiency genetic susceptibility
the strategic use of hyaluronic acid fillers and neurotoxin to influence gender perception in transgender individuals

Conditions: Gender Dysphoria

Summary: observational survey study of transgender individuals who have undergone cosmetic neurotoxin and soft tissue filler for the purpose of influencing gender perception.


Eligibility criteria:
inclusion criteria: * healthy male or female transgender volunteer * has the desire to alter gender perception and is seeking treatment with neurotoxin and soft tissue filler * subjects with an already existing treatment plan * willing to sign photography release, with the understanding the de-identified photographs may be used in medical publications or presentations for the purposes of education * females of childbearing potential who are sexually active are using a reliable method of contraception1 at least one month before the beginning of the study, and throughout the study * must be informed about the study objectives and procedures, and be able to understand them * willing and able to fulfill the study requirements and schedule * willing to give their written informed consent exclusion criteria: * individuals who underwent a neurotoxin procedure on the face within 6 months of study start * individuals who underwent an injectable filler procedure on the face within 1 year of study start * individuals who underwent surgical procedure on the face for the purpose of gender reassignment or cosmetic enhancement at any point in time before study start individuals who have planned cosmetic treatments or surgeries during the course of the study * individuals with dental procedures performed 30 days before, during, or 30 days after the course of the study * individuals who participated within the 30 days before inclusion or currently participating in another clinical study involving the investigational areas * individuals with known or suspected defect of healing * individuals with any disease state or inappropriate physical skin condition that might impair evaluations or increase the health risk to the subject by participation in the opinion of the investigator * individuals unable to be contacted by phone in case of emergency * individuals who are currently participating in any other clinical trial or have participated in any clinical trial involving the investigation area within 30 days prior to inclusion into the study.
proprioception and multi sensory training after drf

Conditions: Distal Radius Fracture; Wrist Fracture

Summary: distal radius fracture is the most common upper extremity fracture with peak incidence among older women after the fifth decade of life. proprioception is one constituent of a complex sensory motor control process. proprioception requires the reception and central integration of incoming afferent signals. although various sensory and motor deficits have been correlated with significant functional impairment after wrist trauma, limited research exists on the effects of proprioception and multi sensory training after distal radius fracture.

a randomized, controlled, single-center, double-blind, clinical trial, with 1:1 allocation ratio, will be carried out involving patients diagnosis of distal radius fracture (aged 18 years and above). both assessor and statistician will remained blinded. standard rehabilitation program for distal radius fracture treatments will received for both the control and experimental groups for a period of 12 weeks. the experimental group, in addition, will received a proprioceptive training program during the same intervention period, which will be conducted twice weekly (24 sessions). the severity of pain with activity will be measured according to the visual analog scale (vas). prwe questionnaire will be used to measure upper extremity function. patient's occupational performance will be measured with the canadian occupational performance measure (copm) and proprioception with joint position sense (jps) and force sense (fs) testing. all outcome measures will be collected at baseline, immediately following the intervention at 3 weeks and at 12 weeks following the end of the intervention. participation in the study will be voluntary and patients will be included if they satisfied specific inclusion criteria. all procedures will be follow in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the helsinki declaration. all participants will sign a written informed consent in accordance with guidelines approved by the local ethics committee.

Eligibility criteria:
inclusion criteria: * patient diagnosis of distal radius fracture. * wrist immobilization after lesion (unless 3 weeks) * capacity for sing inform concept and understand the exercises exclusion criteria: * others associate fractures in hand or upper limb * wrist ligaments injuries * neurological disorder affecting the upper limb * have received previous proprioceptive training for upper limb injury.
follow-up for locking plate fixaion of distal radius fracture

Conditions: Distal Radius Fracture

Summary: the current status of the disease under study. including natural history, disease prognosis. distal radial fractures (drf, distal radius fractures) are the most common fractures, allowing the user to lock the steel plate to accelerate the recovery of the wrist, but related injuries such as the triangular fibrocartilage cartilage complex (tfcc) tear or distal radius ulna joint (druj) ligament tear with druj instability requires time fixed or further repair surgery. if these issues are ignored, there will be weakness in the future. the ulnar shortening commonly used by hand surgeons is to improve the damage of tfcc or druj instability. in the case of distal radial fracture combined with druj instability, it is not clear that the distal radial fracture combined with druj instability patients has long-term prognosis.


Eligibility criteria:
inclusion criteria: * outpatient following for at least one year exclusion criteria: * (1) injury or arthritis before; (2) open fractures, or more wounds require surgery

Keywords: locking plate fixaion
study of fx005 for the treatment of pain in patients with osteoarthritis of the knee

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of fx005 for the treatment of pain in patients with osteoarthritis of the knee.

the objectives of the study are to assess fx005, as compared to placebo control, for: * safety and tolerability * analgesic effect * pharmacokinetics analgesic effect will be assessed using the western ontario \& mcmaster university osteoarthritis index (womac), the measure of intermittent and constant osteoarthritis pain (icoap) questionnaire, and patient and clinical observer global assessments.

Eligibility criteria:
inclusion criteria: * male or female ≥40 years of age * diagnosis of unilateral or bilateral osteoarthritis of the knee for at least 6 months; confirmation of osteoarthritis according to american college of rheumatology criteria (clinical and radiological) * kellgren-lawrence grades ii or iii * mean score for the womac a subscale (pain) between 2.0 and 3.5 for the index knee * score of 2-3 for the womac a1 score (pain on walking) for the index knee * body mass index ≤ 40 kg/m2 * willingness to abstain from use of restricted medications during the study * willingness and ability to comply with the study procedures and visit schedule exclusion criteria: * kellgren-lawrence grade 0, i or iv radiographic stage of the index knee * clinically apparent tense effusion in index knee * presence of surgical hardware or other foreign body in the index knee * clinical signs and symptoms of active knee infection or crystal disease * intra-articular corticosteroid within 3 months of screening * intra-articular hyaluronic acid within 6 months of screening * other intra-articular therapy within 3 months of screening * prior arthroscopic or open surgery of the index knee within 12 months of screening * planned/anticipated surgery of the index knee during the study period * history of malignancy or other serious, non-malignant, significant, acute or chronic medical (e.g.. uncontrolled diabetes) or active psychiatric illness * skin breakdown at the knee where the injection would take place * women who are pregnant, nursing or likely to become pregnant during the time of the study * women of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year) not using effective contraception

Keywords: osteoarthritis knee intra-articular safety efficacy pharmacokinetics pain
telemedical risk assessment and preoperative evaluation (tape)

Conditions: Patients Undergoing Elective Surgery With Anesthesia

Summary: the purpose of this study is to assess the feasibility, patient satisfaction and time saving of a telemedical risk assessment and preoperative evaluation for anesthesia.

the preanesthesia evaluation and risk assessment is conducted by an anesthesiologist prior to elective surgery. the physician assesses the patient´s medical records and specifies the individual preoperative procedure in order to minimize the perioperative risks. the on-site meeting is often connected with extended travel time and during the covid-19 pandemic also with an increased infection risk for the patient. this project was initiated to reduce time efforts on patient site and to reduce possible infection risks. the tape-software turns every patients home into a remote facility allowing the physician to conduct the preanesthesia evaluation over distance.

Eligibility criteria:
inclusion criteria: * ≥18 years * estimated asa i/ii classification based on the american society of anesthesiologists (asa) classification * elective surgery * surgery at least 14 days in the future * patient access to a windows-10-based personal computer with webcam exclusion criteria: * language or cognitive barriers (e.g. dementia, laryngectomy...) * high risk surgeries with need of postoperative icu stay * acute infection with required auscultation
switching to iloperidone from other antipsychotics in schizophrenia

Conditions: Schizophrenia

Summary: evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.


Eligibility criteria:
inclusion criteria: * males or females, 18 to 64 years of age, inclusive * dsm-iv diagnosis of schizophrenia * patients currently on an optimal in-label dose of one of the following permitted antipsychotic treatments for at least 30 days: risperidone, olanzapine, or aripiprazole * efficacy clinical global impression of severity (e-cgi-s) of 4 or 5 or * not tolerating one of the permitted treatments and exhibits one of the allowable side-effects exclusion criteria: * any other current axis i disorder other than schizophrenia which is the focus of treatment; * acutely psychotic or patient's symptom severity requires hospitalization * patient with significant cardiovascular illness (myocardial infarction, cardiac arrhythmia) other protocol-defined inclusion/exclusion criteria may apply

Keywords: schizophrenia iloperidone switch gradual switch immediate switch
the evaluation of glycyrrhizic acid's pesticide effect in treating liver damage (retrospective study）

Conditions: Liver Damage

Summary: collect the details about hepatic dysfunctional patients induced by various etiology who have a usage of glycyrrhizic acid, then arrange and analyse the data to evaluate the clinical curative effect of glycyrrhizic acid.

this experiment will screen and collect qualified cases from medical records in shuguang hospital.to collect the patients with liver injury in clinic, including (1) conforms to alt\>1.5 times the normal value or \>70 iu/l, age 18 to 70 years of age, sex is not limited; (2) patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ; (3) except for tumor patients. the index of liver function such as alt, ast, alb, et al are detected respectively before and after preventive treatment of the glycyrrhizic acid for liver injury ,and through the synthesizing of the single sample difference t test and clinical practice to analyze the clinical efficacy of glycyrrhizin intervention treatment of hepatic injury

Eligibility criteria:
inclusion criteria: 1. conforms to alt\>1.5 times the normal value or \>70iu/l, age 18 to 70 years of age, sex is not limited; 2. patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ; exclusion criteria: 1. patients with tumor; 2. pregnant or lactating women, and pregnancy may not take effective contraceptive measures; 3. complicated with serious heart, lung, gallbladder, kidney, endocrine, hematopoietic system and mental disease; 4. the researchers think that should not be selected for this test.
efficacy and safety of sa58 nasal spray in close contact with covid-19 people

Conditions: COVID-19

Summary: this is a randomized, single-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sa58 nasal spray in close contact with covid-19 people.

this study is a randomized, single-blind, placebo-controlled clinical trial in close contacts to covid-19. the investigational drug was manufactured by sinovac life sciences co. , ltd.the purpose of this study is to estimate the efficacy and safety of sa58 nasal spray in close contacts to covid-19. a total of 2900 subjects were planned to be enrolled,including 2300 subjects who were non-continuous exposed to covid-19 in group a,600 subjects who were continuous exposed to covid-19 in group b. all subjects started medication on the day of enrollment. during the medication period, the subjects were given nasal spray once every 3 hours,about 5-6 times a day.

Eligibility criteria:
inclusion criteria: * subjects aged 18 years and above on the day of enrollment; * had recent contact with an infected person, and the time of pcr sampling from a positive infected person, or the time of first contact with a positive infected person should not exceed 72 hours; * the subjects can understand and voluntarily sign the informed consent form; exclusion criteria: * previous history of severe allergy or sensitivity to inhalation allergens; * women are breastfeeding, pregnant, or planning to become pregnant during the study period; * participated in clinical trials of sars-cov-2 neutralizing antibody injections within 180 days prior to screening or clinical trials of other drugs within 4 weeks prior to screening; * subjects unable to cooperate with nasal spray inhalation; * body temperature at baseline (day 0)\>37.0℃; * had a severe neurological disorder (epilepsy, convulsions or convulsions) or psychosis, and have a family history of psychosis; * the researchers determined that the subjects had a serious chronic medical condition that could interfere with the conduct or completion of the study; * according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
hddo-1614 bio equivalence study

Conditions: Osteoporosis

Summary: a randomized, open-label, single-dose, crossover study

this clinical trial is conducted with a randomized, open-label, single-dose, and cross over study designs. investigators will compare the pharmacokinetic parameters of test drug(single oral dose, single administration) with pharmacokinetic parameters of comparator 1 and 2(combined administration, single oral dose).

Eligibility criteria:
inclusion criteria: * body weight 50kg ≤ / bmi=18\~29kg/㎡ * a person who is determined to be eligible for the test through a physical examination or an interview * those who have been judged to be eligible for the clinical laboratory tests such as hematology test, blood chemistry test, urine test, and serology test exclusion criteria: * patients with clinically significant liver, pancreas, kidney, nervous system, respiratory, endocrine, hematologic, mental, cardiovascular * patients with a history of gastrointestinal disorders or history of gastrointestinal surgery that may affect the absorption of pharmaceuticals for clinical trials * any person who shows any of the following results in the screening test 1. ast or alt \> 2 times upper limit of normal range 2. total bilirubin \> 2.0mg/dl 3. glomerular filtration rate(egfr) \< 60ml/min/1.7㎡ * those who show signs of hypotension (systolic blood pressure ≤ 100mm hg or diastolic blood pressure ≤ 55mmhg) or hypertension (systolic blood pressure ≥ 150mmhg or diastolic blood pressure ≥ 95mmhg) * those who have a history of drug or who have a positive urine drug test
randomized, double-blind, vehicle-controlled, multicenter safety and efficacy study of intraprostatic prx302 for luts bph

Conditions: Benign Prostatic Hyperplasia

Summary: the purpose of this study is to evaluate the safety and efficacy of a single treatment of prx302 for the treatment of benign prostatic hyperplasia (bph) as compared to placebo.


Eligibility criteria:
inclusion criteria: * age ≥50 years * lower urinary tract symptoms (luts) attributable to bph for ≥6 months * ipss ≥15 * maximum urine flow (qmax) of 5 - 15 ml/sec * prostate volume of 30 - 100 ml as determined by trus * serum prostate-specific antigen (psa) values \<10 ng/ml * post-void residual (pvr) \<= 200 ml exclusion criteria: * inability to void ≥125 ml urine * prior surgery/mist for bph * presence of or history of certain conditions that could interfere with study results or endanger subject * use of certain prescribed medications that could interfere with study results

Keywords: benign prostatic hyperplasia bph enlarged prostate lower urinary tract symptoms (luts)
efficacy and tolerability of testogel/nebido in combination with exercise and diet in hypogonadal male patients

Conditions: Hypogonadism

Summary: with advancing age testosterone levels decline in men. low testosterone levels plus certain symptoms are called "late onset hypogonadism (loh)". adipose tissue may contribute to testosterone deficiency. on the other hand testosterone deficiency again leads to a decrease in lean body mass and an increase in fat mass - one of the clinical signs / symptoms of loh. lifestyle changes (diet, exercise) alone or in combination with testosterone replacement (trt), have an influence on the symptoms of loh. the aim of this study is to assess the additional impact of trt on aging male symptom score (ams) and adiposity (waist circumference) in patients, who are on a diet and exercise program.


Eligibility criteria:
inclusion criteria: * male patients \> 35yrs * waist circumference \> 102cm * clinically and biochemically confirmed hypogonadism (testosterone group) * willingness to attempt weight optimization exclusion criteria: * androgen dependent carcinoma of the prostate or male mammary gland, past or present history of liver tumours * hypersensitivity towards the active pharmaceutical ingredient or other ingredients.

Keywords: hypogonadism abdominal obesity physical exercise testosterone